pharmaphorum January 13, 2025
Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.
Just nine months after emerging from stealth with a $290 million Series A and two months after adding another $215 million to the pot in a Series B, the New York-based company has filed with the Securities & Exchange Commission (SEC) to list on the Nasdaq under the ‘MTSR’ symbol.
The filing – given a $100 million placeholder value by Renaissance Capital, but which could raise considerably more – would help the company accelerate the clinical development of its pipeline of obesity candidates as it chases down market leaders Novo Nordisk and Eli Lilly alongside an ever-lengthening list of...
Today's Sponsors
Today's Sponsor